USE OF PENTOXIFYLLINE IN TREATMENT OF ORAL SUBMUCOUS FIBROSIS: AN ORIGINAL RESEARCH

被引：0

作者：

Bolla, Vijaya Lakshmi ^{[1
]}

Khanna, Shilpa Sunil ^{[2
]}

Teji, Apoorva Venkata P. ^{[3
]}

Divya, D. ^{[4
]}

Mor, Reena ^{[5
]}

Swathi, T. ^{[6
]}

Tiwari, Rahul V. C. ^{[7
]}

机构：

[1] Govt Dent Coll & Hosp, Dept Periodont, Hyderabad, Telangana, India

[2] Sri Ramakrishna Dent Coll & Hosp, Dept Oral & Maxillofacial Surg, Coimbatore 641006, Tamil Nadu, India

[3] Meghna Inst Dent Sci, Dept Oral & Maxillofacial Surg, Nizamabad, Telangana, India

[4] New Special Dent Clin, Trichur, Kerala, India

[5] Surendera Dent Coll & Res Ctr, Oral & Maxillofacial Surg, Sri Ganganagar, Rajasthan, India

[6] Meenakshi Ammal Dent Coll & Hosp, Meenakshi Acad Higher Educ Res, Dept Oral Med & Radiol, Chennai, Tamil Nadu, India

[7] Sankalchand Patel Univ, NarsinhbhaiPatel Dent Coll & Hosp, Dept OMFS, Visnagar, Gujarat, India

来源：

INTERNATIONAL JOURNAL OF EARLY CHILDHOOD SPECIAL EDUCATION | 2022年 / 14卷 / 03期

关键词：

Oral submucous fibrosis; pentoxifylline; therapy;

D O I：

10.9756/INT-JECSE/V14I3.102

中图分类号：

G76 [特殊教育];

学科分类号：

040109 ;

摘要：

Aim The objective of this clinical study was designed to determine the effect of pentoxifylline on progression of oral submucous fibrosis while comparing it to the placebo treatment. Methodology 75 patients suffering from oral submucous fibrosis were randomly divided into two groups A and B. Group A patients received placebo, while Group B patients received 400 mg. Pentoxifylline for a period of 7 months. Treatment outcome was evaluated on the basis of improvement in symptom and sign scores. Student's 't' test was applied for comparing the results. Results The improvement in total (i.e. symptoms + sign) score was 25% in group A and 49.15% in group B. This difference was found to be statistically significant. (p < 0.05) Conclusion Treatment regimen of group B was more effective. No significant side effects were seen. A follow up study is required to assess long term outcome of this therapy.

引用

页码：810 / 813

页数：4

共 15 条

[1]

Aara A, 2012, GLOBAL J MED RES, V12, P169

[2]

[Anonymous], 2008, COCHRANE DB SYST REV

[3] Lack of reliable evidence for oral submucous fibrosis treatmentsWhat treatments are effective in managing restricted jaw opening or movement in people who have oral submucous fibrosis? [J].

Shahid R Aziz .

Evidence-Based Dentistry, 2009, 10 (1) :8-9

[4] Oral submucous fibrosis. A review [J].

Cox, SC ;

Walker, DM .

AUSTRALIAN DENTAL JOURNAL, 1996, 41 (05) :294-299

[5]

Gupta J, 2012, E J DENT, V2, P132

[6]

Gupta S C., 1978, Indian J Otolaryngol, V30, P5

[7]

Joshi SG., 1953, INDIAN J OTOLARYNGOL, V4, P1

[8]

Mehrotra R, 2011, ASIAN PAC J CANCER P, V12, P971

[9] Correlation of addictive factors, human papilloma virus infection and histopathology of oral submucous fibrosis [J].

Mehrotra, Ravi ;

Chaudhary, Ajay Kumar ;

Pandya, Shruti ;

Debnath, Sharmistha ;

Singh, Mangal ;

Singh, Mamta .

JOURNAL OF ORAL PATHOLOGY & MEDICINE, 2010, 39 (06) :460-464

[10]

Patil S, 2014, Journal of Orofacial Sciences, V6, P94, DOI [10.4103/0975-8844.143048, DOI 10.4103/0975-8844.143048]

← 1 2 →